These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 35306748)

  • 1. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
    Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
    J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
    Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
    BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgery for Hepatocellular Carcinoma With Macroscopic Vascular Invasion in the Era of Modern Molecular Therapy.
    Yamamura K; Beppu T; Miyata T; Mima K; Okabe H; Nitta H; Imai K; Hayashi H; Oda E; Karashima R; Ozaki N; Isiko T
    Anticancer Res; 2023 Oct; 43(10):4285-4293. PubMed ID: 37772548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.
    Hidaka Y; Tomita M; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
    World J Surg Oncol; 2022 Jul; 20(1):228. PubMed ID: 35831894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion Surgery for Hepatocellular Carcinoma Following Molecular Therapy.
    Yamamura K; Beppu T; Miyata T; Okabe H; Nitta H; Imai K; Hayashi H; Akahoshi S
    Anticancer Res; 2022 Jan; 42(1):35-44. PubMed ID: 34969706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Xu H; Zhang H; Li B; Chen K; Wei Y
    BMC Cancer; 2024 Aug; 24(1):1008. PubMed ID: 39143584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody.
    Xu B; Zhu XD; Shen YH; Zhu JJ; Liu J; Li ML; Tang PW; Zhou J; Fan J; Sun HC; Huang C
    Front Immunol; 2022; 13():1016736. PubMed ID: 36505445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic treatment for unresectable hepatocellular carcinoma.
    Leowattana W; Leowattana T; Leowattana P
    World J Gastroenterol; 2023 Mar; 29(10):1551-1568. PubMed ID: 36970588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.
    Kudo M
    World J Gastroenterol; 2019 Feb; 25(7):789-807. PubMed ID: 30809080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study.
    Li X; Wang X; Bai T; Chen J; Lu S; Wei T; Tang Z; Zhao G; Lu H; Li L; Wu F
    Dig Liver Dis; 2024 Jun; 56(6):1078-1086. PubMed ID: 38114383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial).
    Ichida A; Arita J; Hatano E; Eguchi S; Saiura A; Nagano H; Shindoh J; Hashimoto M; Takemura N; Taura K; Sakamoto Y; Takahashi Y; Seyama Y; Sasaki Y; Uemura K; Kokudo N; Hasegawa K
    Liver Cancer; 2024 Jun; 13(3):322-334. PubMed ID: 38894811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma.
    Takamoto T; Maruki Y; Kondo S
    Expert Opin Pharmacother; 2023; 24(14):1567-1575. PubMed ID: 37357809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative Chemotherapy Followed by Hepatectomy for Potentially Resectable UICC7 Stage IIIA, IIIB Hepatocellular Carcinoma; A Phase II Clinical Trial.
    Goto Y; Niizeki T; Fukutomi S; Shirono T; Shimose S; Iwamoto H; Kojima S; Kanno H; Uchino Y; Sasaki S; Shirahama N; Muroya D; Nomura Y; Akashi M; Nakayama G; Hirakawa Y; Sato T; Yoshitomi M; Sakai H; Hisaka T; Kakuma T; Koga H; Torimura T; Akagi Y; Okuda K
    Kurume Med J; 2023 Sep; 68(3.4):239-245. PubMed ID: 37518005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma.
    Chen J; Zhang D; Yuan Y
    Clin Exp Med; 2023 Jul; 23(3):579-590. PubMed ID: 36018466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Therapy for Hepatocellular Carcinoma: 2017 Update.
    Kudo M
    Oncology; 2017; 93 Suppl 1():135-146. PubMed ID: 29258077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Minimally Invasive Conversion Hepatectomy for Advanced Hepatocellular Carcinoma].
    Sakai H; Goto Y; Shimose S; Niizeki T; Kawaguchi T; Akiba J; Yano H; Akagi Y; Fujita F; Hisaka T
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1572-1574. PubMed ID: 38303345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
    Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
    Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
    [No Abstract]   [Full Text] [Related]  

  • 18. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
    Eggert T; Greten TF
    Digestion; 2017; 96(1):1-4. PubMed ID: 28605745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
    Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
    Front Immunol; 2022; 13():913464. PubMed ID: 35677059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review.
    Tang H; Cao Y; Jian Y; Li X; Li J; Zhang W; Wan T; Liu Z; Tang W; Lu S
    Biosci Trends; 2022 May; 16(2):130-141. PubMed ID: 35431288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.